Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.
How this was made
The 30-second read
Why it matters
The 30‑day results provide the first efficacy and safety signals for the medium‑size valve, a key milestone before the pivotal PARADIGM trial.
Market read
Positive early data could attract investor interest and support the stock ahead of larger trial readouts.
What to watch
Regulatory approval timeline and competition from established TAVR manufacturers could temper upside.
Background
Anteris Technologies (NASDAQ: AVR) is a medical‑device company developing the DurAVR transcatheter heart valve.
Ticker impact
Anteris announced 30‑day clinical outcomes for its medium‑size DurAVR THV, showing favorable hemodynamics and no mortality.
likely upward pressure as market prices in favorable early‑stage results
First disclosure of medium‑size DurAVR outcomes with strong metrics; no prior data released.
Market effects
May lift sentiment for the broader transcatheter aortic valve replacement (TAVR) sector.
Potentially supportive for US and Australian biotech markets where Anteris is listed.
Limited to cardiovascular device niche; modest global impact.
Counterpoint
Early‑stage data may not translate to long‑term outcomes; investors should watch for larger pivotal trial results.
Key entities
- companyAnteris Technologies
Developer of the DurAVR transcatheter heart valve.
- clinical_trialPARADIGM Trial
Randomized study comparing DurAVR to commercial TAVRs.
